Back to Journals » OncoTargets and Therapy » Volume 17

LEF1-AS1, a Long Non-Coding RNA, Promotes Malignancy in Glioblastoma [Retraction]

Authors Wang J, Liu X, Yan C, Liu J, Wang S, Hong Y, Gu A, Zhao P

Received 18 January 2024

Accepted for publication 18 January 2024

Published 19 January 2024 Volume 2024:17 Pages 3—4

DOI https://doi.org/10.2147/OTT.S460244



Wang J, Liu X, Yan C, et al. Onco Targets Ther. 2017;10:4251–4260.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figure 5 with images from other unrelated articles. Specifically,

  • Images for Figure 5E, Ki-67, have been duplicated with images for Figure 3E from Zhang X, Lian T, Fan W, et al. Long-Noncoding RNA CASC9 Promotes Progression of Non-Small Cell Lung Cancer by Promoting the Expression of CDC6 Through Binding to HuR. Cancer Manag Res. 2020;12:9033–9043. https://doi.org/10.2147/CMAR.S268375.

The authors did not respond to our queries and were unable to provide an explanation for the duplicated images or provide data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.